Cardiovascular Toxicity in Cancer Therapy: Protecting the Heart while Combating Cancer
- PMID: 39042344
- DOI: 10.1007/s11886-024-02099-2
Cardiovascular Toxicity in Cancer Therapy: Protecting the Heart while Combating Cancer
Abstract
Purpose of review: This review explores the cardiovascular toxicity associated with cancer therapies, emphasizing the significance of the growing field of cardio-oncology. It aims to elucidate the mechanisms of cardiotoxicity due to radiotherapy, chemotherapy, and targeted therapies, and to discuss the advancements in human induced pluripotent stem cell technology (hiPSC) for predictive disease modeling.
Recent findings: Recent studies have identified several chemotherapeutic agents, including anthracyclines and kinase inhibitors, that significantly increase cardiovascular risks. Advances in hiPSC technology have enabled the differentiation of these cells into cardiovascular lineages, facilitating more accurate modeling of drug-induced cardiotoxicity. Moreover, integrating hiPSCs into clinical trials holds promise for personalized cardiotoxicity assessments, potentially enhancing patient-specific therapeutic strategies. Cardio-oncology bridges oncology and cardiology to mitigate the cardiovascular side-effects of cancer treatments. Despite advancements in predictive models using hiPSCs, challenges persist in accurately replicating adult heart tissue and ensuring reproducibility. Ongoing research is essential for developing personalized therapies that balance effective cancer treatment with minimal cardiovascular harm.
Keywords: 3D models; Cardiotoxicity; Chemotherapy; Pharmacogenomics; iPSCs.
© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Similar articles
-
Modeling Precision Cardio-Oncology: Using Human-Induced Pluripotent Stem Cells for Risk Stratification and Prevention.Curr Oncol Rep. 2021 May 3;23(7):77. doi: 10.1007/s11912-021-01066-2. Curr Oncol Rep. 2021. PMID: 33937943 Free PMC article. Review.
-
Strategies to Prevent Cardiotoxicity.Curr Treat Options Oncol. 2020 Apr 8;21(4):32. doi: 10.1007/s11864-020-0722-6. Curr Treat Options Oncol. 2020. PMID: 32270293 Review.
-
Recent advances in pluripotent stem cell-derived cardiac organoids and heart-on-chip applications for studying anti-cancer drug-induced cardiotoxicity.Cell Biol Toxicol. 2023 Dec;39(6):2527-2549. doi: 10.1007/s10565-023-09835-4. Epub 2023 Oct 27. Cell Biol Toxicol. 2023. PMID: 37889357 Review.
-
Personalized medicine in cardio-oncology: the role of induced pluripotent stem cell.Cardiovasc Res. 2019 Apr 15;115(5):949-959. doi: 10.1093/cvr/cvz024. Cardiovasc Res. 2019. PMID: 30768178 Free PMC article. Review.
-
Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management.CA Cancer J Clin. 2016 Jul;66(4):309-25. doi: 10.3322/caac.21341. Epub 2016 Feb 26. CA Cancer J Clin. 2016. PMID: 26919165 Review.
References
-
- Miller KD, Nogueira L, Devasia T, Mariotto AB, Yabroff KR, Jemal A, et al. Cancer treatment and survivorship statistics, 2022. CA Cancer J Clin. 2022;72(5):409–36. https://doi.org/10.3322/caac.21731 . - DOI - PubMed
-
- Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7–33. https://doi.org/10.3322/caac.21708 . - DOI - PubMed
-
- Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17–48. https://doi.org/10.3322/caac.21763 . - DOI - PubMed
-
- Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74(1):12–49. https://doi.org/10.3322/caac.21820 . - DOI - PubMed
-
- Mariotto AB, Noone AM, Howlader N, Cho H, Keel GE, Garshell J, et al. Cancer survival: an overview of measures, uses, and interpretation. J Natl Cancer Inst Monogr. 2014;2014(49):145–86. https://doi.org/10.1093/jncimonographs/lgu024 . - DOI - PubMed - PMC
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials